TrialJournal of Crohn's & colitis2018

Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.

Sudha Visvanathan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.